Sensitive detection of boron-containing drug delanzomib by a luminescence probe in health-related samples

Abstract

Background: Boron-containing drugs are widely used in anti-inflammatory, anti-bacterial, anti-tumor and other applications, thus it is important to develop methods for their detection. However, the sensitive detection of delanzomib through its boric acid group remains challenging because of steric hindrance and interference from its own fluorescence.

Results: We report an iridium(III) complex containing the 1,2-dione group for the detection of delanzomib for the first time. Complex 1 shows significantly decreased luminescence at 580 nm upon addition of delanzomib in aqueous solution. Complex 1 has good sensitivity and selectivity for delanzomib with a linear relationship in the range of 1-30 μM and a limit of detection (LOD) of 0.628 μM and a limit of quantification (LOQ) of 1 μM. Furthermore, complex 1 is successfully applied for the monitoring of delanzomib in health-related samples.

Significance: This study provides a solid basis for the advancement of analytical tools for the monitoring of boron-containing drugs.

Keywords: Delanzomib; Iridium(III) complex; Luminescent probe.